Email alerts

Subscribe to our mailing list

Testimonials

Since Tri-Solfen® was commercially launched, over 150 million lambs have been treated and over 80% of Australian wool growers are now using Tri-Solfen for their sheep. Here’s what some of them have to say…

‘We have used pain relief for two years now and seen real production gains. We are concerned for the welfare of our animals and will continue to use pain relief to ensure they get the best care.’

Clinton Wise– Wililoo Merino Stud, Woodanilling, W.A.

'It easy to see the difference pain relief makes. Before, lambs would walk away hunched up, even taking a couple of hours to walk back to the paddock. Now they run straight back to Mum and start suckling,” says Rod. “My wool is now sold under the Better Choices brand. I see this as a definite advantage. I think it will be an advantage in the long run, to both me and the industry as a whole.'

Rod Miller– Glenpaen Merino Stud, Horsham, Vic

'After being treated with pain relief my lambs were more content and less stressed. As farmers we are sincere in looking after the welfare of our animals and using pain relief demonstrates this.'

Richard Coole– Frankland, W.A.

'We have been using pain relief for the past three years. We’re impressed by reduced bleeding in the mulesing wound immediately after application. Lambs run straight back to find the ewe, which has dramatically reduced our mortality rates. Flock management, post lamb marking is easier due to the effect of pain relief and the scab healing faster.'

Ryan & Malcom O’Dea– Peepingee Merino Stud, Narrogin, W.A.

'Using pain relief eases the stress and allows lambs to mother up and move back to the paddock easier with faster weight gains.'

Kent Lummis– Waverley Downs, Gilgandra, NSW

Close

Patent Portfolio

Country Species Patent
Australia Sheep Granted
Australia Horses, Dogs, Lab animals Granted
Australia Cattle Granted
Australia Humans Granted
New
Zealand		 Sheep,
Cattle		 Granted
New
Zealand		 Horses, Dogs, Lab animals Granted
EU Humans Granted
EU Pig, Sheep,
Cattle		 Granted
USA Dogs, Horses, Lab animals Granted
USA Humans Granted
USA Pig, Sheep,
Cattle		 Granted
Canada Horses, Dogs, Lab animals Granted
Canada Cattle,
Pig		 Granted
Canada Humans Granted

Close

Advisory Board

Ian Page

Non-Executive Director

Ian is Chief Executive Officer of Dechra Pharmaceuticals, which has a 33% shareholder in Medical Ethics. He joined National Veterinary Services, Dechra’s former services business in 1989 and joined the Board of Dechra in 1997. In October 2010, Ian was appointed as Non-Executive Chairman of Sanford DeLand Asset Management.

Dr Chris Roberts

Human Wound and Regulatory Advisor

Chris has over 20 years’ line management experience of heading clinical research teams. He was previously global head of Smith & Nephew clinical support and market development, where he managed global clinical Phase II and III programmes in the management of venous and pressure ulcers.

Lieutenant Colonel Professor Steven Jeffery

Medical Specialist Advisor

Steve has over 15 years’ experience in military plastic surgery. In 2011 he was awarded the Military Civilian Partnership Award for ‘Regular of the Year’, as well as receiving the Wounds UK ‘Key Contribution’ award and the Smith and Nephew ‘Customer Pioneer of the Year’ award. He has also been awarded Fellowship of the Royal College of Surgeons of England ad eundum. He is an expert adviser to NICE Medical Technologies Evaluation Programme. Steve co-founded the Woundcare 4 Heroes charity, which is already making a big difference to the wound care of both serving and veteran personnel.

Dr Matthew Bayfield

Medical Specialist Scientific Director

Dr Matthew Bayfield, Head of Cardiothoracic Surgery, Strathfield Private Hospital and VMO Cardiothoracic Surgeon, Royal Prince Alfred Hospital.

Professor Peter Windsor

Veterinarian Research Advisor

Peter is a registered specialist veterinary surgeon in New South Wales and an emeritus Professor at Sydney University. He holds a BVSc (Hons), PhD, DVSc and diploma from the European College of Small Ruminant Health Management.

Dr Julian Braidwood

Global Regulatory Affairs Advisor

Julian has held leadership roles and managed international clinical projects with Grampian. He was previously Regulatory Affairs Manager at Novartis Animal Health. He is the Founder and Managing Director of Triveritas, where he is responsible for a team of 40 animal health specialists across the EU and the US.

Close

Animal Ethics pain product extended for use in Australian calves

December 19, 2016

Australian regulatory authorities have extended the use of the anesthetic and antiseptic topical application Tri-Solfen to include the alleviation of pain in calves.

The product, which is manufactured by domestic firm Animal Ethics, was previously approved by the Australian Pesticides and Veterinary Medicines Authority for use in lambs during October 2016. It is currently used in over eight million animals per year in Australia – alleviating pain from procedures such as castration, tail docking and mulesing.

Now, the over-the-counter product has been extended for use in calves. Tri-Solfen has a three-way action designed to numb the animal’s wound, minimize bleeding and protect against infection.

According to Animal Ethics, trials have demonstrated pain alleviation for up to 24 hours in both calves and lambs after surgical castration. These trials also showed a significant improvement in wound healing.

Allan Giffard, managing director of Animal Ethics, said: “It is a major win for farmers, a win for calves, a win for animal welfare and a win for the Australian cattle and dairy industries. Tri-Solfen is now approved to provide a practical means for farmers to alleviate the pain associated with husbandry procedures in calves and lambs, which are relied on for important animal health and management reasons.

“This in turn has been shown to improve mothering-up, minimize set-back, whilst also addressing consumer concerns over welfare.”

Piglet extension coming

The latest regulatory extension further broadens the scope of Tri-Solfen, which has been used to treat 70 million animals to date.

The next step for the product is another label extension, this time to allow its use in piglets. Studies are being carried out by Sydney University Veterinary School to support this extension, which Animal Ethics predicts will be granted in the first half of 2017.

Aside for adding extra indications to the product’s claims, the firm is also taking Tri-Solfen to wider markets through partnerships.

Mr Giffard added: “This is a very exciting milestone for our company and the new calf registration further strengthens our marketing approval platform as we accelerate our international registration program in key markets such as the US, EU, Canada, South Africa, New Zealand and South America.”  READ FULL ARTICLE